P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom
P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom is a paper indexed in PICO Portal from OpenAlex.
How many citations does P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom have?
P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom has 0 citations in the OpenAlex counts PICO Portal stores.
When was P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom published?
P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom has 2024 year in the PICO Portal index.
What is the open-access status of P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom?
P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom has closed oa status in the PICO Portal index.
What is the DOI of P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom?
The DOI for P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom is on the source record.
What is the OpenAlex record for P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom?
The OpenAlex for P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom is on the source record.